Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.42 |
| ▸ | DHFR | P00374 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526712 | 0.82 | PTPN1 (0.45) | PTPN1HRH4DHFRHRH1HRH3 | |
| SCHEMBL4511017 | 0.78 | DHFR (0.47) | PTPN1DHFRNLRP3 | |
| Trifluoroacetic Acid SCHEMBL4510973 | 0.77 | PTPN1 (0.41) | PTPN1HRH4DHFRHRH1HRH3 | |
| SCHEMBL4523209 | 0.77 | PTPN1 (0.67) | PTPN1HRH4HRH1HRH3NLRP3 | |
| SCHEMBL4510977 | 0.76 | PTPN1 (0.40) | PTPN1HRH4DHFRHRH1HRH3 | |
| SCHEMBL4528809 | 0.74 | DHFR (0.65) | PTPN1HRH4DHFRNLRP3 | |
| SCHEMBL4527626 | 0.74 | PTPN1 (0.68) | PTPN1HRH4NLRP3 | |
| SCHEMBL28768395 | 0.74 | NLRP3 (0.36) | HRH4DHFRHRH3NLRP3 | |
| SCHEMBL4516229 | 0.72 | PTPN1 (0.44) | PTPN1HRH4DHFRHRH1HRH3 | |
| SCHEMBL4532712 | 0.72 | DHFR (0.61) | PTPN1HRH4DHFRNLRP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1229937-B1 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QUADRA LOGIC TECH INC (CA) | 2007-11-07 | — | — | EP | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | PTPN1 2/4885HRH4 3834/4885DHFR 2071/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | PTPN1 2/4885HRH4 3834/4885DHFR 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.